Bydureon Tracker App
Track Exenatide Extended-Release Weekly Doses and HbA1c in Shotlee
Bydureon (exenatide extended-release 2 mg) is a once-weekly GLP-1 receptor agonist for type 2 diabetes, FDA approved in January 2012. It uses a unique microsphere depot formulation that releases exenatide slowly over 7 days — a single fixed dose with no escalation required. The Bydureon BCise autoinjector (approved 2017) eliminated manual reconstitution. DURATION-1 demonstrated -1.6% HbA1c at 30 weeks.
What Is Bydureon (Exenatide Extended-Release)?
Bydureon is the extended-release formulation of exenatide — the first GLP-1 receptor agonist ever approved (the twice-daily version, Byetta, launched in 2005). Bydureon uses PLGA microspheres (poly-lactic-co-glycolic acid) to encapsulate exenatide and release it over 7 days after a single subcutaneous injection. This depot technology converts a twice-daily peptide into a once-weekly medication.
A single fixed dose of 2 mg per week is used for all patients — there is no titration schedule. The Bydureon BCise pen (approved 2017) further simplified administration by pre-mixing the microsphere suspension, eliminating the multi-step manual reconstitution required by the original Bydureon vial. While less potent than newer agents like semaglutide or tirzepatide, Bydureon remains an established option with a long safety record and a fixed, simple weekly dosing structure.
DURATION-1 Clinical Results (30 Weeks)
How to Inject Bydureon BCise Correctly
What to Track in Shotlee
Fixed weekly dosing means consistency in technique matters most — track every injection and outcome metric in Shotlee.
Protocol FAQs
Both contain exenatide, but Byetta is twice-daily injection (5 or 10 mcg) and Bydureon is once-weekly extended-release (2 mg). Bydureon provides more consistent drug levels, less nausea, and comparable or slightly better HbA1c reduction. DURATION-1 showed Bydureon reduced HbA1c by 1.6% vs twice-daily exenatide.
Small firm bumps at the injection site are common with Bydureon due to the PLGA microspheres. They are typically not painful and resolve within 4–8 weeks. Rotating injection sites every week reduces nodule accumulation. Log injection sites in Shotlee to maintain proper rotation.
The EXSCEL trial showed non-inferiority but not superiority for MACE vs placebo in T2D patients. Unlike semaglutide (SUSTAIN-6, SELECT) and liraglutide (LEADER), Bydureon has not demonstrated CV superiority. It is considered CV-safe but not specifically cardioprotective.
Bydureon remains prescribed, particularly where cost or formulary access is a factor. It has a long safety record since 2012 and the BCise autoinjector is well-tolerated. However, semaglutide and tirzepatide deliver meaningfully greater HbA1c and weight reduction for patients who can access them.
Exenatide ER released from microspheres takes 6–7 weeks to reach steady-state plasma concentrations. Initial HbA1c response may be modest and should be assessed at 3 months when steady state is established. Track your HbA1c at each clinic visit in Shotlee.
Track Your Bydureon Protocol in Shotlee
Log weekly injections, injection site reactions, HbA1c, and weight progress — free in Shotlee.